Industry Daily Summary
Industry Daily Summary: What Happened on October 30, 2026
Lilly raises 2026 outlook as Mounjaro and Zepbound sales climb
The two drugs generated about $16.1 billion in third-quarter sales. AstraZeneca is seeking $1.5 billion in annual savings by 2029.
-
P
Today in brief
Eli Lilly raised its 2026 revenue outlook to $91 billion to $92 billion as Mounjaro and Zepbound sales increased 65% and 59%, respectively.1
Lilly lifts outlook after 39% revenue growth
Eli Lilly’s third-quarter revenue rose 39% from a year earlier, prompting the company to raise its 2026 outlook to $91 billion to $92 billion from $85 billion to $87 billion.1 Mounjaro generated $10.7 billion in global sales and Zepbound $5.4 billion, for about $16.1 billion combined.1 Revenue growth slowed from 48% in the second quarter, with pricing pressure cited as a factor.1
Also worth knowing
-
P
AstraZeneca is seeking $1.5 billion in annual savings by the end of 2029.2
Also published
- Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game BioPharma Dive
- Sanofi eyeing pipeline deals ahead of Dupixent patent loss pharmaphorum
- Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3) Labiotech
- Orbis and AlzeCure change CEOs; Simris hires another Heidelberg Pharma veteran European Biotechnology
- Navigating geopolitical risks: Practical and legal mitigations for the pharmaceutical industry pharmaphorum
- Lilly's tirzepatide juggernaut is still gathering momentum pharmaphorum